← Back to patent-cliff list
CAS 146-78-1
(2R,3R,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
Codes: REGA-011
Application context (from source-drug indications)
Cardiovascular contrast agentRegadenoson HydrateDiagnostic agentRegadenoson HydrateContrast imagingRegadenoson HydrateCoronary artery lesionRegadenoson HydrateIschaemic heart diseaseRegadenoson HydratePneumoniaRegadenoson Hydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Regadenoson Hydrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
ethyl 1H-pyrazole-4-carboxylate→N-methyl-1H-pyrazole-4-carboxamide→(2R,3R,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.